Rekah Pharmaceutical Industry Ltd.

TASE:REKA Stock Report

Market Cap: ₪149.6m

Rekah Pharmaceutical Industry Dividend

Dividend criteria checks 2/6

Rekah Pharmaceutical Industry is a dividend paying company with a current yield of 6.62%.

Key information

6.6%

Dividend yield

n/a

Payout ratio

Industry average yield1.9%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-₪0.61
Dividend yield forecast in 3Yn/a

Recent dividend updates

No updates

Recent updates

Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Dec 14
Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet

Sep 12
Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet

Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)

Jul 19
Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)

Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit

Apr 13
Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit

We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt

May 12
We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt

Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today

Apr 09
Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today

Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?

Mar 12
Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?

Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 19
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?

Jan 29
Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?

Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock

Jan 08
Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock

How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?

Dec 18
How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?

Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%

Nov 30
Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Whilst dividend payments have been stable, REKA has been paying a dividend for less than 10 years.

Growing Dividend: REKA has only been paying a dividend for 2 years, and since then payments have not increased.


Dividend Yield vs Market

Rekah Pharmaceutical Industry Dividend Yield vs Market
How does REKA dividend yield compare to the market?
SegmentDividend Yield
Company (REKA)6.6%
Market Bottom 25% (IL)2.4%
Market Top 25% (IL)6.9%
Industry Average (Pharmaceuticals)1.9%
Analyst forecast in 3 Years (REKA)n/a

Notable Dividend: REKA's dividend (6.62%) is higher than the bottom 25% of dividend payers in the IL market (2.39%).

High Dividend: REKA's dividend (6.62%) is low compared to the top 25% of dividend payers in the IL market (6.9%).


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate REKA's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonable cash payout ratio (59.9%), REKA's dividend payments are covered by cash flows.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.